{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Shi Y"],"pubmed_abstract":["<h4>Background</h4>Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum <i>vs.</i> that of pemetrexed plus platinum alone as the first-line therapy for patients with nonsquamous NSCLC to inform clinically rational drug use and provide a basis for medical decision-making.<h4>Methods</h4>A partitioned survival model was created to evaluate the cost-effectiveness of two groups from the perspective of the healthcare system"],"journal":["Translational cancer research"],"pagination":["928-938"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10175008"],"repository":["biostudies-literature"],"pubmed_title":["Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer."],"pmcid":["PMC10175008"],"pubmed_authors":["Li G","Li Y","Qian D","Bo M","Jia B","Chen W","Zhang M","Shi J","Dai Y","Shi Y"],"additional_accession":[]},"is_claimable":false,"name":"Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.","description":"<h4>Background</h4>Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum <i>vs.</i> that of pemetrexed plus platinum alone as the first-line therapy for patients with nonsquamous NSCLC to inform clinically rational drug use and provide a basis for medical decision-making.<h4>Methods</h4>A partitioned survival model was created to evaluate the cost-effectiveness of two groups from the perspective of the healthcare system","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-04T13:51:28.969Z","creation":"2025-04-04T13:51:28.969Z"},"accession":"S-EPMC10175008","cross_references":{"pubmed":["37180653"],"doi":["10.21037/tcr-22-2030"]}}